نتایج جستجو برای: fulvestrant

تعداد نتایج: 782  

2015
Pedram Heidari Francis Deng Shadi A. Esfahani Alicia K. Leece Timothy M. Shoup Neil Vasdev Umar Mahmood

Purpose: Estrogen receptor (ER) targeting is key in management of receptor-positive breast cancer. Currently, there are no methods to optimize anti-ER therapy dosing. This study assesses the use of 16a-F-fluoroestradiol (F-FES) PET for fulvestrant dose optimization in a preclinical ERþ breast cancer model. Experimental Design: In vitro, F-FES retentionwas compared with ERa protein expression (E...

Journal: :Cancer letters 2014
Tove Kirkegaard Susanne K Hansen Sarah L Larsen Birgit E Reiter Boe S Sørensen Anne E Lykkesfeldt

In this study, T47D cell lines resistant to the antiestrogen fulvestrant were established and analyzed to explore, whether a switch to HER signaling, as seen in fulvestrant resistant MCF-7 cell lines, is a general resistance mechanism. We find that parental T47D cells depend on ER and HER signaling for growth. Fulvestrant resistant T47D cells have lost ER expression and, although HER2 was over ...

Journal: :Clinical journal of oncology nursing 2003
Linda Versea Margaret Rosenzweig

Fulvestrant, the first drug of the pure estrogen antagonists to be approved for clinical use, is a new therapeutic option for metastatic breast cancer. Fulvestrant offers a unique metastatic breast cancer treatment option because its mechanism of action is the destruction, rather than the blockade, of estrogen receptors. No known agonistic activity exists, limiting potential side effects and re...

2017
Jingwen Zhang Yanhong Huang Changyi Wang Yuanfang He Shukai Zheng Kusheng Wu

BACKGROUND Endocrine therapy was recommended as the preferred first-line treatment for hormone receptor-positive (HR+, i.e., ER+ and/or PgR+), human epidermal growth factor receptor-2-negative (HER2-) postmenopausal advanced breast cancer (ABC), but which endocrine monotherapy is optimal lacks consensus. We aimed to identify the optimal endocrine monotherapy with a network meta-analysis. METH...

Journal: :Endocrine-related cancer 2006
Anthony Howell

For more than 30 years, tamoxifen has been the drug of choice in treating patients with oestrogen receptor (ER)-positive breast tumours. However, research has endeavoured to develop agents that match and improve the clinical efficacy of tamoxifen, but lack its partial agonist effects. The first 'pure' oestrogen antagonist was developed in 1987; from this, an even more potent derivative was deve...

2017
Yuan Huang Donghai Jiang Meihua Sui Xiaojia Wang Weimin Fan

Drug resistance, a major obstacle to successful cancer chemotherapy, frequently occurs in recurrent or metastatic breast cancer and results in poor clinical response. Fulvestrant is a new type of selective estrogen receptor (ER) downregulator and a promising endocrine therapy for breast cancer. In this study, we evaluated the combination treatment of fulvestrant and doxorubicin in ER-negative m...

2017
Jingchao Bai Guanglin Zhou Yufan Qiu Yunhui Hu Jingjing Liu Jing Zhao Sheng Zhang Jin Zhang

Hormone therapy has become one of the main strategies for breast cancer, however, many estrogen receptor (ER) positive patients end in tumor collapse due to initial or acquired resistance to hormone treatment, which includes Fulvestrant. Here we report that ErbB receptors and downstream PI3K/AKT and ERK pathway have been reactivated after treatment of Fulvestrant in ER positive MCF-7 and T47D c...

2014
Wisit Tangkeangsirisin Ginette Serrero W. Tangkeangsirisin G. Serrero

The 88 kDa glycoprotein known as GP88, Progranulin or PC cell derived growth factor is an autocrine growth factor with a unique cysteine rich motif that is over expressed in breast cancer whereas it is negative in normal mammary epithelial cells. It has been shown to play a major role in estrogen independence, tamoxifen resistance and tumorigenesis of breast cancer cells. In the present study, ...

Journal: :Cancer research 2006
Jingyung Hur Daphne W Bell Kathleen L Dean Kathryn R Coser Pablo C Hilario Ross A Okimoto Erica M Tobey Shannon L Smith Kurt J Isselbacher Toshi Shioda

Induction of mRNA for BIK proapoptotic protein by doxorubicin or gamma-irradiation requires the DNA-binding transcription factor activity of p53. In MCF7 cells, pure antiestrogen fulvestrant also induces BIK mRNA and apoptosis. Here, we provide evidence that, in contrast to doxorubicin or gamma-irradiation, fulvestrant induction of BIK mRNA is not a direct effect of the transcriptional activity...

Journal: :Cancers 2021

Introduction: Fulvestrant has demonstrated efficacy in hormone receptor positive (HR+) metastatic breast cancer (mBC), both first-and second-line settings. In clinical practice, however, fulvestrant been used as a later-line therapy. This study assessed the of women with mBC early-versus Methods: retrospective cohort Saskatchewan HR+ who received between 2003–2019. A multivariate Cox proportion...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید